Increased serum circulatory levels of interleukin 17F in type 1 reactions of leprosy

Journal of Clinical Immunology

Volumn 32, Issue 6, 2012, Pages 1415-1420

  Chaitanya, Sundeep ^a   Lavania, Mallika ^a   Turankar, Ravindra P ^a   Karri, Samuel Raj ^a   Sengupta, U ^a  

^a Stanley Browne Research Laboratory The Leprosy Mission Community Hospital   (India)

Author keywords

bacteriological index (BI); delayed type hypersensitivity reactions; Erythema Nodosum Leprosum (ENL); Proinflammatory cytokines; Ridley DS and Jopling WH Classification; type 1 reactions

Indexed keywords

INTERLEUKIN 17F; BIOLOGICAL MARKER; IL17F PROTEIN, HUMAN; INTERLEUKIN 17;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA NODOSUM LEPROSUM; FEMALE; HUMAN; IMMUNOMODULATION; LEPROSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVERSAL REACTION; SCHOOL CHILD; BLOOD; BORDERLINE LEPROSY; CASE CONTROL STUDY; ERYTHEMA NODOSUM; IMMUNOLOGY; LEPROMATOUS LEPROSY; MIDDLE AGED; MYCOBACTERIUM LEPRAE; PATHOLOGY; PHYSIOLOGY; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHEMA NODOSUM; FEMALE; HUMANS; INTERLEUKIN-17; LEPROSY, BORDERLINE; LEPROSY, LEPROMATOUS; MALE; MIDDLE AGED; MYCOBACTERIUM LEPRAE;

EID: 84878223131     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9747-3     Document Type: Article

References (35)

1. Lupi O, Madkan V, Tyring SK. Tropical dermatology: bacterial tropical diseases. J Am Acad Dermatol. - April 2006.
2. Withington SG, Maksuda AN, Hamid Salim MA, Ahmed JU. Current status of leprosy and leprosy control in Bangladesh: an ongoing collaboration. Lepr Rev. 2005;76(3):209-19.
3. WHO - Weekly Epidemiological Record 2011. 2 September 2011, No. 36, 2011, 86, 389-400.
4. Lockwood DN, Colston MJ, Khanolkar-Young SR. The detection of Mycobacterium leprae protein and carbohydrate antigens in skin and nerve from leprosy patients with type 1 (reversal) reactions. Am J Trop Med Hyg. 2002;66(4):409-15.
5. Ridley DS, Jopling WH. Classification of leprosy according to immunity: a five-group system. Int J Lepr. 1966;34:255-73.
6. Walker SL, Lockwood DNJ. The clinical and immunological features of leprosy. Br Med Bull. 2006;77-78(1):103-21.
7. Walker SL, Lockwood DN. Leprosy types 1 (reversal) reactions and their management. Lepr Rev. 2008;79(4):372-86.
8. Kawaguchi M, Kokubu F, Huang SK, Homma T, Odaka M, Watanabe S, et al. The IL-17F signaling pathway is involved in the induction of IFN-gamma-inducible protein 10 in bronchial epithelial cells. J Allergy Clin Immunol. 2007;119(6):1408-14.
9. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006;116(5):1218-22.
10. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of TH17 cells. Nature. 2008;453:1051-7.
11. Cruz A, Khader SA, Torrado E, Fraga A. Cutting edge: IFN-regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. J Immunol. 2006;177:1416-20.
12. Khader SA, Cooper AM. IL-23 and IL-17 in tuberculosis. NIH-PA Author Manuscrip. Cytokine. 2008;41(2):79-83.
13. Kahawita IP, Walker SL, Lockwood DNJ. Leprosy type 1 reactions and erythema nodosum leprosum. An Bras Dermatol. 2008;83(1):75-82.
14. Steinhoff U, Kaufmann SH. Specific lysis by CD8+ T cells of Schwann cells expressing Mycobacterium leprae antigens. Eur J Immunol. 1988;18(6):969-72.
15. Narayanan RB, Girdhar BK, Malaviya GN, Sengupta U. In situ demonstration of Mycobacterium leprae antigens in leprosy lesions using monoclonal antibodies. Immunol Lett. 1990;24(3):179-83.
16. Spierings E, De Boer T, Zulianello L, Ottenhoff TH. Novel mechanisms in the immunopathogenesis of leprosy nerve damage: the role of Schwann cells, T cells and Mycobacterium leprae. Immunol Cell Biol. 2000;78(4):349-55.
17. Goulart IM, Cardoso AM, Santos MS, Gonçalves MA, Pereira JE, Goulart LR. Detection of Mycobacterium leprae DNA in skin lesions of leprosy patients by PCR may be affected by amplicon size. Arch Dermatol Res. 2007;299(5-6):267-71.
18. Oliveira RB, Ochoa MT, Sieling PA, Rea TH, Rambukkana A, Sarno EN, Modlin RL. Expression of Toll-like receptor 2 on human Schwann cells: a mechanism of nerve damage in leprosy. Infect Immun. 2003;71(3):1427-33.
19. Scollard DM. The biology of nerve injury in leprosy. Lepr Rev. 2008;79(3):242-53.
20. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol. 2007;148(1):32-46.
21. Qin H, Wang L, Feng T, Elson CO, Niyongere SA, Lee SJ, Reynolds SL, Weaver CT, Roarty K, Serra R, Benveniste EN, Cong Y. TGF-beta promotes Th17 cell development through inhibition of SOCS3. J Immunol. 2009;183(1):97-105.
22. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008;8(5):337-48. doi: 10.1038/nri2295.
23. Manel N, Unutmaz D, Littman DR. The differentiation of human TH-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol. 2008;9(6):641-9. doi: 10.1038/ni.1610.
24. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28(4):454-67. doi: 10.1016/j.immuni.2008.03.004.
25. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235-8. doi: 10.1038/nature04753.
26. Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature. 2007;448(7152):484-7. doi: 10.1038/nature05970.
27. Robert L. Modlin. Th1-Th2 paradigm: insights from leprosy. J Invest Dermatol. 1994;102:828-32. doi: 10.1111/1523-1747.ep12381958.
28. Khader VSA, Gopal R. IL-17 in protective immunity to intracellular pathogens. Virulence. 2010;1(5):423-7.
29. Hamza T, Barnett JB, Li B. Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci. 2010;11(3):789-806.
30. Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, Quesniaux V, Fossiez F, Ryffel B, Schnyder B. Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med. 2006;203(12):2715-25.
31. Martiniuk F, Giovinazzo J, Tan AU, Shahidullah R, Haslett P, Kaplan G, Levis WR. Lessons of leprosy: the Emergence of TH17 cytokines during type II reactions (ENL) is teaching us about T-cell plasticity. J Drugs Dermatol. 2012;11(13):626-30.
32. Stefani MM, Guerra JG, Guerra ALM, et al. Potential plasma markers of type 1 and type 2 leprosy reactions: a preliminary report. BMC Infect Dis. 2009;9:75. doi: 10.1186/1471-2334-9-75.
33. Lockwood DNJ, Suneetha L, Sagili KD, Chaduvula MV, Mohammed I, et al. Cytokine and protein markers of leprosy reactions in skin and nerves: baseline results for the North Indian INFIR cohort. PLoS Negl Trop Dis. 2011;5(12):e1327. doi: 10.1371/journal.pntd.0001327.
34. Jadhav R, Suneetha L, Kamble R, Shinde V, Devi K, et al. Analysis of antibody and cytokine markers for leprosy nerve damage and reactions in the INFIR cohort in India. PLoS Negl Trop Dis. 2011;5(3):e977. doi: 10.1371/journal.pntd.0000977.
35. Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 2007;17:435-40. doi: 10.1038/cr.2007.35.